health
February 9, 2026
Novo Nordisk pops 7% after Hims & Hers pulls copycat Wegovy weight-loss pill
Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.
TL;DR
- Hims & Hers will stop selling its compounded semaglutide pill, a Wegovy copycat, following pressure from Novo Nordisk and the FDA.
- Novo Nordisk shares rose over 6% on Monday after the announcement.
- The FDA had threatened legal action and stated it would take "decisive steps" to restrict compounding pharmacies' practices of selling unapproved drug copies.
- Hims & Hers stated the decision was made after "constructive conversations with stakeholders across the industry."
- Novo Nordisk views the action by Hims & Hers as "illegal mass compounding that poses a significant risk to patient safety."
- Novo Nordisk has ramped up manufacturing and resolved supply restraints for its semaglutide products.
Continue reading the original article